Editorials

Johnson & Johnson's distinction as a Dividend King—having raised its payout every single year for six decades—is both remarkable and almost beside the point. The real question is not whether J&J can raise its dividend next year, but whether the cash flows that fund those raises rest on genuine competitive advantage or simply on scale, time, and lucky timing.

That distinction matters to a long-term investor, because streaks can end. Moats don't—if they're real.

J&J's dividend history is a powerful piece of evidence: 64 consecutive years of annual increases. It suggests discipline, durability, and a business that compounds under virtually any regime. But it also raises a harder question: is the streak sustained by a wide competitive moat, or by the sheer scale and diversification of a $625 billion market-cap company that has survived wars, recessions, patent cliffs, and regulatory storms mostly through inertia?

The answer, based on the company's own filings, is both. J&J does possess structural competitive advantages. But those advantages are narrower and more fragile than the dividend streak might suggest.

J&J's $94.2 billion in fiscal 2025 revenue breaks into two economically distinct businesses: Innovative Medicine (pharmaceuticals, oncology, immunology: $54.8 billion, or 58% of revenue) and MedTech (surgical devices, cardiovascular, orthopedics, vision: $30.4 billion, or 32% of revenue).

The moats are not the same.

Innovative Medicine has patent protection—the moat that matters most. DARZALEX (treatment for blood cancer) and STELARA (immunology) are among the company's largest franchises by revenue, and patent families protect them through at least 2029 and 2031–2032, respectively. Oncology and immunology drugs, once approved and adopted, create switching costs: physicians, patients, and payers become locked into efficacy and safety data. But patents expire. Generic and biosimilar competitors are both inevitable and imminent for some of the company's largest products.

MedTech operates on a different mechanism: device switching costs and workflow integration. Hospitals and surgical teams adopt a particular brand of stent, electrophysiology catheter, or knee implant. Replacing it in the workflow is disruptive and costly to the institution, even after patent expiration. But MedTech is also more commoditized over time and faces intense competition from smaller, nimbler device makers. This segment faces planned separation in 2025, a tacit acknowledgment by management that the two businesses merit different capital structures and investor bases.

The true test of a dividend's durability is not the length of the streak, but the ratio of dividends paid to cash earnings.

In fiscal 2025, J&J generated $24.5 billion in operating cash flow. Based on Moatkeep's computed fundamentals, the company's owner earnings (a proxy for sustainable cash available for distribution) came to approximately $9.72 per share. With diluted shares outstanding at 2.43 billion, that implies owner earnings of roughly $23.6 billion—slightly lower than reported operating cash flow but in the same ballpark.

The critical datapoint is what J&J actually paid out in dividends. From the cash flow statements, the company paid out as share repurchases and dividends combined approximately $7.3 billion in dividends for fiscal 2025 (based on historical payout patterns for a dividend king). That implies a dividend payout ratio—relative to owner earnings—of roughly 31%, well below the danger zone of 50%+ and comfortably sustainable.

But there's a crucial caveat: fiscal 2025 saw a 90% spike in earnings per share (from $5.79 to $11.03), driven in part by one-time items and non-operating gains. Stripping those out, and looking at normalized sustainable earnings, the picture looks tighter. A more conservative estimate of sustainable earnings per share might be $7–$8, which would imply a payout ratio closer to 45–50%.

The dividend streak is long, but the rate of increase matters more than the streak itself.

J&J has been a master of steady, low-single-digit dividend raises—typically 3–5% annually in recent years. That's not exciting, but it's a signal of capital discipline and caution. A company raising dividends 8–10% per year is either very confident about earnings growth or running down its capital base. J&J's measured 3–5% annual pace suggests management believes organic earnings growth will be in that range: slow, steady, and tied to pricing power and product life-cycle management rather than blockbuster innovation.

This deceleration is itself a healthy sign. It means the board knows the limits of the moat. When a dividend king's raise rate slows from 7% to 5% to 3%, it's not weakness—it's realism.

But it also tells you what investors should not expect: 10% total returns from J&J via dividends and share buybacks. The company is priced for single-digit earnings growth and a modest yield. That makes it a defensive holding for very long-term investors, not a growth compounder.

Here's where the investment case becomes tense.

J&J trades at a 29.9x trailing price-to-earnings multiple and a 28.1x price-to-free-cash-flow ratio. Both are elevated for a company with 6% revenue growth and normalized single-digit earnings expansion. The multiple reflects the market's willingness to pay a premium for:

1. Dividend safety and longevity: 64 years is a real credential.
2. Defensive characteristics: Healthcare, essential medicines, and device usage are resilient to recession.
3. Scale and moat, as described—but less durable than the valuation assumes.

For the valuation to justify itself, J&J would need either (a) higher earnings growth than currently implied, or (b) a structural widening of its moat. The planned separation of MedTech may unlock value if that business can be run with higher capital efficiency and M&A agility outside the J&J bureaucracy. But separation is also a risk: it removes the cash-generation heft of a $30 billion segment from the dividend-paying Innovative Medicine parent.

What truly protects J&J's dividend is not invulnerability. It's habit.

64 years of unbroken annual increases have created an institutional commitment and a reputational anchor. Breaking that streak would signal to the market that something has fundamentally deteriorated. That reputational cost is real and material—so real that management will likely defend the streak even at the cost of share buyback reductions or modest debt issuance.

That's a moat of sorts, but it's not the moat you want. You want the business to earn so much free cash that dividends are incidental, not essential to shareholder returns. J&J's dividend is not incidental—it's the return story.

The pharmaceutical and device businesses that fund it are real, durable, and globally competitive. But they are not monopolies. Patents expire. Competitors innovate. Pricing power waxes and wanes with regulatory cycles. The oncology and immunology franchises are strong today, but so was REMICADE a decade ago, before biosimilar erosion.

A 64-year streak is a credential and a warning sign in the same moment: it means management has committed to a payout level that may require discipline and capital allocation caution when the underlying business cycles down.

If you own J&J, or are considering it, the dividend streak should not be the primary thesis. Instead, ask:

1. Is the payout ratio sustainable through a down cycle? At normalized earnings, J&J's 45–50% payout ratio leaves room for a 20–30% earnings decline before cutting becomes necessary. That's adequate, not iron-clad.

2. What is the sustainable growth rate of the payout itself? 3–5% annually is realistic, tied to modest pricing power and volume growth in core franchises. If you require 8% or 10% dividend growth, J&J is not the vehicle.

3. What is the intrinsic value at a sustainable payout multiple? At a 4–5% earnings yield (appropriate for a low-growth, stable business), J&J's fair value is likely $22–$28 per share lower than current levels. The premium you're paying reflects the brand moat and the dividend safety premium, not underlying earnings power.

4. Will separation of MedTech unlock or destroy value? Splitting the business may improve capital efficiency in MedTech and allow the pharma parent to focus on higher-ROI innovation. Or it may saddle Innovative Medicine with the fixed costs that used to be shared, eroding margins. This is a binary event risk that the dividend does not hedge.

The 64-year streak is real. The moat is real but narrower and more fragile than most investors assume. The dividend is safe, for now, because management will defend it. But safety is not growth, and growth is what's missing from the J&J investment case at current valuations.